Dr. Reddy’s Laboratories informs about press release

05 Jun 2023 Evaluate

Dr. Reddy’s Laboratories has informed that it enclosed a press release titled ‘Dr. Reddy’s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1166.90 0.45 (0.04%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×